Treatment-Adjusted Cross-Sectional Associations of Serum Calprotectin, Sialic Acid, and Pannexin-1 with Interstitial Lung Disease in Treated Rheumatoid Arthritis
Aktuelle Rheumatologie · 2026-09-08
DOI: 10.1055/a-2909-5126 ↗Abstract
Abstract Most RA-ILD biomarker studies enroll patients receiving treatment, which may alter inflammatory activity. We investigated whether calprotectin, sialic acid, and pannexin-1 show treatment-adjusted cross-sectional associations with ILD status in patients receiving treatment for RA. This cross-sectional case-control study included 154 participants (49 patients with HRCT-confirmed RA-ILD, 55 RA patients without ILD, 50 healthy controls). Serum biomarkers were measured by ELISA. The primary multivariate logistic regression model for ILD status within the RA cohort was adjusted for age, sex, smoking status, and binary biologic DMARD and corticosteroid use, with VIF, L1/L2 penalized, parsimonious model, rituximab-exclusion resampling, and bootstrap-CI ROC sensitivity analyses. In Bonferroni-corrected pairwise testing between RA-ILD and RA without ILD, no biomarker reached p
EUVIMED